Biomarkers predicting the effect of anti‐TNF treatment in paediatric and adult inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition · 2024
DOI: 10.1002/jpn3.12221 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Dwight A Winter und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Infliximab, Biomarkers, Adalimumab, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sophia Children's Hospital Research Fund, Investigator-Initiated Studies Programme of MSD Netherlands.
Abstract (Originalsprache)
Objectives
Paediatric and adult inflammatory bowel disease (pIBD, aIBD) patients may lose response to anti‐tumour necrosis factor (TNF) treatment within the first year. Adult‐extrapolated weight‐based dosing is incorrect in children, due to age‐related pharmacokinetic differences. We investigated biomarkers for initial and maintenance of response to infliximab (IFX) or adalimumab (ADA), comparing pIBD and aIBD patients.
Methods
In this prospective, observational study, pIBD ( n = 24) and aIBD ( n = 21) patients were included when initiating anti‐TNF. Escalation from standard dosing and continued anti‐TNF at 12 and 18 months were assessed. Biomarkers included clinical laboratory parameters, faecal calprotectin (FCP) and IFX trough levels (TLs). Plasma proteomics was performed in pIBD.
Results
During our study, treatment escalation (in clinical loss of response) occurred more common in pIBD versus aIBD ( p = 0.02). We established that IFX therapy escalation in pIBD patients was not due to low infliximab levels. We identified 9 pro‐inflammatory proteins that were elevated in patients losing response.
Conclusion
Anti‐TNF exposure‐response relationship may be different in pIBD versus aIBD. No biomarkers for maintained response were identified, but 9 inflammatory proteins were of interest as potential predictors for loss of response in pIBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands.
- Department of Pediatrics, Ghent University Hospital, Ghent University, Ghent, Belgium.
- Department of Gastroenterology, Erasmus MC, Rotterdam, Netherlands.
- Department of Biostatistics, Erasmus MC, Rotterdam, Netherlands.
- Laboratory of Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands.
Förderung
- Sophia Children's Hospital Research Fund
- Investigator-Initiated Studies Programme of MSD Netherlands
Zitieren
APA
Winter, D. A., de Bruyne, P., van der Woude, J., Rizopoulos, D., de Ridder, L., Samsom, J., & Escher, J. C. (2024). Biomarkers predicting the effect of anti‐TNF treatment in paediatric and adult inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12221
Vancouver
Winter DA, de Bruyne P, van der Woude J, Rizopoulos D, de Ridder L, Samsom J, et al. Biomarkers predicting the effect of anti‐TNF treatment in paediatric and adult inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12221
BibTeX
@article{Winter2024,
author = {Winter, Dwight A and de Bruyne, Pauline and van der Woude, Janneke and Rizopoulos, Dimitris and de Ridder, Lissy and Samsom, Janneke and Escher, Johanna C},
title = {Biomarkers predicting the effect of anti‐TNF treatment in paediatric and adult inflammatory bowel disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
doi = {10.1002/jpn3.12221}
}
EUVIMED